Serum total 8-iso-prostaglandin F2α: A new and independent predictor of peripheral arterial disease

Mueller, Thomas; Dieplinger, Benjamin; Gegenhuber, Alfons; Haidinger, D; Schmid, Nina; Roth, Nitzan; Ebner, F.; Landl, M.; Poelz, Werner; Haltmayer, Meinhard

doi:10.1016/j.jvs.2004.07.044

Cited by 43 publications

(34 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors suggest that low statistical power could have been a contributing factor with 227 cases and 417 matched controls. This finding disagrees with cross-sectional studies that have shown F 2α -isoprostanes to be predictive for peripheral artery [80] and coronary artery disease [81].…”

Section: Lipid Peroxidation and Cardiovascular Diseasecontrasting

confidence: 98%

Oxidative stress biomarkers as predictors of cardiovascular disease

Strobel

Fassett

Marsh

et al. 2011

International Journal of Cardiology

130

View full text Add to dashboard Cite

Section: Lipid Peroxidation and Cardiovascular Diseasecontrasting

confidence: 98%

Oxidative stress biomarkers as predictors of cardiovascular disease

Strobel

Fassett

Marsh

et al. 2011

International Journal of Cardiology

130

View full text Add to dashboard Cite

“…[26][27][28] For example, it has been reported that circulating levels of 8-isoprostane were an independent risk factor associated with coronary artery disease in a Chinese population (odds ratio 2.47, P < 0.001), 26) and were associated with peripheral artery disease. 27,28) In this study, we have shown that valsartan therapy decreased urine 8-isoprostane levels up to 12 months in type 2 diabetic subjects with hypertension, despite the fact that the blood pressure levels were unchanged. Although carotid artery mean IMT did not decrease after 12 months of treatment in this study, there is a possibility that valsartan treatment of a longer period might inhibit the progression of atherosclerosis via suppression of oxidative stress in type 2 diabetic subjects.…”

Section: Discussionmentioning

confidence: 99%

Effects of 12-Month Valsartan Therapy on Glycation and Oxidative Stress Markers in Type 2 Diabetic Subjects With Hypertension

et al. 2008

View full text Add to dashboard Cite

SUMMARYAlthough it has been reported that angiotensin II receptor blockers inhibited the formation and accumulation of advanced glycation endproducts (AGEs) in vitro and in vivo, whether they can do so clinically is not clear. We investigated the effects of 12-month valsartan therapy on various markers of inflammation, glycation, and oxidation in type 2 diabetic subjects with hypertension.We started 40 mg/day valsartan treatment in 15 type 2 diabetic patients with hypertension. In 6 patients, the dose of valsartan was increased to 80 mg/day after 6 months and maintained until 12 months. Metabolic parameters including BMI and serum high molecular weight (HMW)-adiponectin, high-sensitivity C-reactive protein (hs-CRP) as an inflammation marker, AGEs, paraoxonase activity, platelet-activating factor (PAF)-acetylhydrolase activity, and urine 8-isoprostane levels were measured at baseline and after 6 and 12 months of treatment. Urine microalbumin level and carotid artery intimamedia thickness (IMT) were also measured.Even after valsartan therapy, the blood pressure levels of the patients were not decreased significantly. Serum AGEs and urine 8-isoprostane levels decreased at both 6 and 12 months (P < 0.05 for both), although other metabolic and oxidative markers were unchanged. Though urine microalbumin levels tended to be decreased after 6 and 12 months of valsartan treatment, the changes were not significant. Mean IMT at 12 months was not changed from the baseline value. In conclusion, the findings suggest that treatment with valsartan, even at a low dose, may ameliorate some glycation and oxidative stress markers independently of an effect on blood pressure in hypertensive type 2 diabetic subjects. (Int Heart J 2008; 49: 681-689)

show abstract

“…After adjustment with age, gender, diabetes, hypertension, BMI, creatinine, LDL, triglyceride, high-sensitivity C-reactive protein and homocysteine, an increment of every 10 pg/mL in serum 8-iso-PGF 2a was associated with an increment of 11% in the risk of lower limb ischaemia (OR ¼ 1.11, 95% CI: 1.03-1.20). 36 …”

Section: Peripheral Artery Diseasementioning

confidence: 99%

Systematic review on the association between F₂-isoprostanes and cardiovascular disease

Zhang

2012

Ann Clin Biochem

View full text Add to dashboard Cite

Background: Oxidative stress may play an aetiological role in the development and progression of cardiovascular disease (CVD). However, evidence on its biochemical markers has been controversial. This article aimed to assess the role of F 2 -isoprostanes, a marker for measuring in vivo lipid oxidation, as a biomarker for CVD, including coronary artery disease, stroke and peripheral artery disease. Methods: A literature search was performed using PubMed and EMBASE (from 1966 to February 2012). Studies that investigated the association between F 2 -isoprostanes and CVD were eligible. Results: Of the 22 eligible studies retrieved, 20 studies showed a significant association between F 2 -isoprostanes and CVD. However, to date, there have been only four population-based studies, with one study reporting null association. Although data from prospective studies are ideal to examine a role of such biomarkers in predicting future CVD events, only two studies were prospective. In addition, differences in population characteristics, sample handling/storage and assays, coupled with a lack of confounding adjustment, may all contribute to the enormous variation in previous studies. Conclusions: High levels of F 2 -isoprostanes in urine or blood may be a non-specific indicator of CVD. However, further population-based studies are needed. In addition, multivariable analyses are required for future studies to control confounding and improve classification accuracy.

show abstract

Serum total 8-iso-prostaglandin F2α: A new and independent predictor of peripheral arterial disease

Abstract: Serum total 8-iso-PGF 2alpha was an independent predictor of PAD in the population studied. This finding supports the hypothesis that 8-iso-PGF 2alpha is a risk marker for PAD. Our results indicate increased systemic oxidative stress in patients with PAD.

Cited by 43 publications

References 18 publications

Oxidative stress biomarkers as predictors of cardiovascular disease

Oxidative stress biomarkers as predictors of cardiovascular disease

Effects of 12-Month Valsartan Therapy on Glycation and Oxidative Stress Markers in Type 2 Diabetic Subjects With Hypertension

Systematic review on the association between F₂-isoprostanes and cardiovascular disease

Contact Info

Product

Resources

About

Serum total 8-iso-prostaglandin F2α: A new and independent predictor of peripheral arterial disease

Abstract: Serum total 8-iso-PGF 2alpha was an independent predictor of PAD in the population studied. This finding supports the hypothesis that 8-iso-PGF 2alpha is a risk marker for PAD. Our results indicate increased systemic oxidative stress in patients with PAD.

Cited by 43 publications

References 18 publications

Oxidative stress biomarkers as predictors of cardiovascular disease

Oxidative stress biomarkers as predictors of cardiovascular disease

Effects of 12-Month Valsartan Therapy on Glycation and Oxidative Stress Markers in Type 2 Diabetic Subjects With Hypertension

Systematic review on the association between F2-isoprostanes and cardiovascular disease

Contact Info

Product

Resources

About

Systematic review on the association between F₂-isoprostanes and cardiovascular disease